Compare FINV & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | URGN |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | China | United States |
| Employees | N/A | 291 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2017 | 2016 |
| Metric | FINV | URGN |
|---|---|---|
| Price | $4.80 | $28.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $12.10 | ★ $29.29 |
| AVG Volume (30 Days) | 877.0K | ★ 955.5K |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | N/A | $129.09 |
| Revenue Next Year | $10.58 | $70.96 |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.51 | $3.42 |
| 52 Week High | $10.90 | $32.37 |
| Indicator | FINV | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.63 | 62.20 |
| Support Level | $4.61 | $17.86 |
| Resistance Level | $5.26 | $30.00 |
| Average True Range (ATR) | 0.16 | 1.90 |
| MACD | -0.02 | 0.19 |
| Stochastic Oscillator | 20.34 | 62.20 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.